ImmunoCellular Therapeutics is a clinical-stage biotechnology company developing immune-based therapies for the treatment of various cancers. Its lead product candidate is ICT-107, a dendritic cell immunotherapy targeting cancer stem cells and cancer antigens, which is in Phase III clinical trials for the treatment of glioblastoma multiforme. The Company is also developing a portfolio of other potential therapeutic immunotherapies to treat various types of cancer.